Preclinical evaluation of a novel c-met inhibitor in a gastric cancer xenograft model using small animal PET

Molecular Imaging and Biology

Volumn 15, Issue 2, 2013, Pages 203-211

  Wiehr, Stefan ^a   Von Ahsen, Oliver ^b   Röse, Lars ^b   Mueller, Andre ^b   Mannheim, Julia G ^a   Honndorf, Valerie ^a   Kukuk, Damaris ^a   Reischl, Gerald ^a   Pichler, Bernd J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

c Met; c Met inhibitor; FDG; FLT; Gastric cancer; PET; Xenograft mouse model

Indexed keywords

ANTINEOPLASTIC AGENT; BAY 853474; CYCLIN D1; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME PHOSPHORYLATION; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; STOMACH CANCER; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALIA; MUS;

EID: 84878522266     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0580-0     Document Type: Article

References (37)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150
2. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909
3. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225
4. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355-365
5. Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12:1004-1012
6. Peschard P, Park M (2007) From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 26:1276-1285
7. Christensen JG, Burrows J, Salgia R (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225:1-26
8. Bottaro DP, Rubin JS, Faletto DL et al (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251:802-804
9. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925
10. Di Renzo MF, Narsimhan RP, Olivero M et al (1991) Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6:1997-2003
11. Liu X, Newton RC, Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16:37-45
12. Soman NR, Correa P, Ruiz BA, Wogan GN (1991) The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci U S A 88:4892-4896
13. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RS (1990) Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 50:6417-6422
14. Kuniyasu H, Yasui W, Kitadai Y et al (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189:227-232
15. Ott K, Herrmann K, Schuster T et al (2011) Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 18:3316-3323
16. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782
17. Chen J, Cheong JH, Yun MJ et al (2005) Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 103:2383-2390
18. Vallbohmer D, Holscher AH, Schneider PM et al (2010) [18F]- fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 102:135-140
19. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
20. Kenny LM, Aboagye EO, Price PM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol (R Coll Radiol) 16:176-185
21. Kukuk D, Reischl G, Raguin O et al (2011) Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med 52:1654-1663
22. Fuchs K, Kukuk D, Reischl G et al (2012) Oxygen breathing affects 3′-deoxy-3′-18F-fluorothymidine uptake in mouse models of arthritis and cancer. J Nucl Med 53:823-830
23. Judenhofer MS, Wehrl HF, Newport DF et al (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14:459-465
24. Reischl G, Blocher A, Wei R et al (2006) Simplified, automated synthesis of 3′-[18F]fluoro-3′-deoxy-thymidine ([18F]FLT) and simple method for metabolite analysis in plasma. Radiochim Acta 94:447-451
25. Hamacher K, Coenen HH, Stocklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238
26. Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516
27. Tseng JR, Kang KW, Dandekar M et al (2008) Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med 49:129-134
28. Cullinane C, Dorow DS, Kansara M et al (2005) An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res 65:9633-9636
29. Cullinane C, Dorow DS, Jackson S et al (2011) Differential (18)F-FDG and 3′-deoxy-3′-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. J Nucl Med 52:1261-1267
30. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
31. Brindle K (2008) New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8:94-107
32. Herrmann K, Ott K, Buck AK et al (2007) Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 48:1945-1950
33. Kameyama R, Yamamoto Y, Izuishi K et al (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36:382-388
34. Mochiki E, Kuwano H, Katoh H et al (2004) Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 28:247-253
35. Sampson ER, Martin BA, Morris AE et al (2011) The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res 26:1283-1294
36. Wen PY, Schiff D, Cloughesy TF et al (2011) A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13:437-446
37. Jin H, Yang R, Zheng Z et al (2008) MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 68:4360-4368